Olmesartan Medoxomil With AmlodipineAKM OLMESARTAN AMLODIPINE
Recommended CardiovascularRestrictedNot applicable line
Hypertension in patients who are not adequately controlled with either angiotensin II receptor antagonist or dihydropyridine calcium channel blocker monotherapy.
2
Submissions
2010–10
On the record
—
ICER range
Cost-min
Cost basis
Decision on record
- Meeting Jul 2010 Recommended Antihypertensive
Access path
- TGA registered · AKM OLMESARTAN AMLODIPINE
TGA label narrower than the PBS population
- Jul 2010Recommended · restricted
Comparator changed: olmesartan medoxomil and amlodipine given concomitantly → olmesartan…
- Jul 2010Recommended · restricted
Comparator changed: olmesartan medoxomil and amlodipine given concomitantly → olmesartan…
- PBS listing · Restricted
RecommendedDeferredNot recommended
Cost-effectiveness
Cost minimisation analysis; no ICER calculated by design.
The submission presented a cost minimisation analysis of olmesartan medoxomil plus amlodipine combination against the individual component products at the current price to pharmacist level. PSD · 2010
Economic model disputed
Decision context
PopulationHypertensive patients not adequately controlled with either olmesartan medoxomil or amlodipine monotherapy.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Jul 2010 | Recommended · restricted | olmesartan medoxomil and amlodipine given concomitantly | — | RCT · DBP reduction |
| Jul 2010 | Recommended · restricted | olmesartan medoxomil and amlodipine as individual component products | — | RCT · DBP |
Similar precedents
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide91%Olmesartan Medoxomil With Hydrochlorothiazide85%Amlodipine Besylate With Valsartan80%Amlodipine (As Besylate) With Valsartan And Hydrochlorothiazide77%Telmisartan With Amlodipine77%Olmesartan Medoxomil76%Perindopril Arginine With Amlodipine Besylate74%Valsartan With Hydrochlorothiazide74%
Regulatory · TGA
Label narrower than PBS population — PBAC restricts to patients inadequately controlled on prior monotherapy (ARB or CCB), a treatment-failure subset of the broad TGA hypertension label.